Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Clariant    CLN   CH0012142631

CLARIANT (CLN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Clariant : Launches Amide/Amine-Free Anti-Static Concentrate for...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/26/2017 | 07:10am CET
  • MEVOPUR® anti-stat tested to new stringent regulations
  • Helps reduce risk and limitations of current technology
  • Maintains anti-static performance even at low humidity levels

Muttenz, September 26, 2017 - Clariant, a world leader in specialty chemicals, announces a new amide/amine-free anti-static masterbatch concentrate for polyethylene films used in pharmaceutical production. The new anti-stat, known under grade name MEVOPUR PEAM 176045, will be introduced at CPhI Worldwide, being held 24 - 26 October 2017 at Messe Frankfurt. Clariant is exhibiting on Stand 42L20.

The introduction is timely due to the changes in industry standards which, by 2020, will limit the acceptability of many of the currently used films that contain amide- and amine-based anti-stats, says Stephen Duckworth, Clariant's Head of Global Segment Medical and Pharmaceutical. For the first time, plastics used in pharma manufacturing, including anti-static films, will need to comply with the same standards as plastics packaging used for finished pharmaceuticals.

'Anti-static additives are routinely incorporated in the polyethylene 'clean-room films' that line containers and dispensers for active pharmaceutical ingredients (APIs), and in the tubes used to transfer powdered and liquid API during drug production. They are important because the anti-static properties help to reduce the risk of dangerous conditions like explosions,' he explained.

The new additive masterbatch concentrate is part of MEVOPUR, the brand of 'Controlled, Consistent and Compliant' products for plastics applications in the medical and pharmaceutical industries.

When incorporated into PE films Clariant's new anti-static provides very good static-dissipating performance and a competitive cost profile relative to alternatives. In addition, it has already been tested to the stricter new United States Pharmacopeia (USP) pharmaceutical standard for pharmaceutical-contacting plastics, which are scheduled to come into force in 2020. The new standard -- USP 'Plastic Components and Systems Used in the Manufacturing of Drug Products' -- will, for the first time, apply the same risk-based assessment of materials. Plastic components and single-use containers are increasingly used in manufacturing processes, particularly biological manufacturing processes. Despite their advantages, these plastic assemblies elicit concerns about chemical compounds that may leach or migrate into finished products and impact product quality or safety.

Historically, these anti-static films have predominantly relied on 'migrating' ethoxylated amine/amide-based anti-stats that had a degree of compliance to regulations for food contacting materials. Risk assessments that define migration limits applying to these additives cut allowable addition rates for amide- and amine-based additives to levels below of what is required for effective anti-static performance. This, in addition to the need to test at lower humidity levels (e.g.: , class VI. European Pharmacopeia and USP 661.1. This data, along with a ISO13485-based manufacturing/quality process, full change-control procedures, and documentation such as Drug Master File, help support the risk-management process of medical device producers. MEVOPUR 'Controlled, Consistent and Compliant' color and additive masterbatch concentrates and fully compounded plastics help manufacturers in the medical and pharmaceutical sectors control and minimize risk, while responding quickly to changing industry standards.

Besides the presence of Healthcare Polymer Solutions at CPhI 2017 please join also the experts from Clariant's Business Unit Industrial & Consumer Specialties in meeting room 'Inspiration 1' in hall 10.2 to discuss and learn about Polyglykol and the Macrogol range.

MEVOPUR® IS A TRADEMARK OF CLARIANT REGISTERED IN MANY COUNTRIES.

Clariant AG published this content on 26 September 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 26 September 2017 05:09:08 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CLARIANT
07:11aCLARIANT : re-launches innovative skin care ingredient to combat effects of air ..
PU
02/20CLARIANT : confirms Permcos as DACH distributor for active ingredients
PU
02/14CLARIANT : opens new masterbatch production site in Saudi Arabia
AQ
02/14CLARIANT : significantly increases growth and further improves profitability in ..
GL
02/13CLARIANT : showcases safe and environmental friendly products at Neo Functional ..
PU
02/12CLARIANT : promoted its high tech solutions for the plastics industry at PlastIn..
PU
02/10Clariant CEO says SABIC deal beats Huntsman merger - newspaper
RE
02/09CLARIANT AG : annual earnings release
02/08CLARIANT : announces regional product debuts for American Coatings Show 2018
PU
02/08CLARIANT : Opens New Plant to Fortify Foothold in Masterbatch Market
AQ
More news
News from SeekingAlpha
02/14Clariant's (CLZNF) CEO Hariolf Kottmann on Q4 2017 Results - Earnings Call Tr.. 
02/14Clariant AG 2017 Q4 - Results - Earnings Call Slides 
02/14Clariant AG reports FY results 
02/03HUNTSMAN-CLARIANT : 'Activist' Investors Torpedo Deal, Then Sell 
01/28Atlantic Investment Management 2017 Annual Letter 
Financials ( CHF)
Sales 2018 6 612 M
EBIT 2018 741 M
Net income 2018 415 M
Debt 2018 1 419 M
Yield 2018 2,26%
P/E ratio 2018 19,22
P/E ratio 2019 17,12
EV / Sales 2018 1,41x
EV / Sales 2019 1,32x
Capitalization 7 907 M
Chart CLARIANT
Duration : Period :
Clariant Technical Analysis Chart | CLN | CH0012142631 | 4-Traders
Technical analysis trends CLARIANT
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Average target price 26,6  CHF
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Hariolf Kottmann Chief Executive Officer & Executive Director
Rudolf Wehrli Chairman
Patrick Jany Chief Financial Officer
Peter Chen Non-Executive Director
Carlo G. Soave Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
CLARIANT-9.58%8 436
ECOLAB-1.80%38 056
SIKA-0.52%17 799
SYMRISE-8.29%10 517
INDORAMA VENTURES PCL--.--%9 064
JOHNSON MATTHEY PLC4.26%8 581